208 related articles for article (PubMed ID: 36093297)
61. 4. Antibody therapy for malignant lymphoma.
Tobinai K
Intern Med; 2007; 46(2):99-100. PubMed ID: 17220608
[TBL] [Abstract][Full Text] [Related]
62. Integrating monoclonal antibodies into the management of mantle cell lymphoma.
Berinstein NL; Mangel J
Semin Oncol; 2004 Feb; 31(1 Suppl 2):2-6. PubMed ID: 15042527
[TBL] [Abstract][Full Text] [Related]
63. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.
Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Belayachi L; Bento L; García-Recio M; Sánchez JM; Villalonga P; Gutiérrez A; Fernández de Mattos S
Br J Haematol; 2016 Sep; 174(6):899-910. PubMed ID: 27220900
[TBL] [Abstract][Full Text] [Related]
64. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
65. Update on mantle cell lymphoma.
Maddocks K
Blood; 2018 Oct; 132(16):1647-1656. PubMed ID: 30154113
[TBL] [Abstract][Full Text] [Related]
66. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
Kanaji N; Ishibashi K; Uno H; Hino N
Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
[TBL] [Abstract][Full Text] [Related]
67. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
[TBL] [Abstract][Full Text] [Related]
68. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop.
Kahl BS; Dreyling M; Gordon LI; Quintanilla-Martinez L; Sotomayor EM
Leuk Lymphoma; 2017 Jul; 58(7):1561-1569. PubMed ID: 28140709
[TBL] [Abstract][Full Text] [Related]
69. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients.
Nguyen DT; Amess JA; Doughty H; Hendry L; Diamond LW
Eur J Haematol; 1999 Feb; 62(2):76-82. PubMed ID: 10052709
[TBL] [Abstract][Full Text] [Related]
70. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.
Mangel J; Leitch HA; Connors JM; Buckstein R; Imrie K; Spaner D; Crump M; Pennell N; Boudreau A; Berinstein NL
Ann Oncol; 2004 Feb; 15(2):283-90. PubMed ID: 14760123
[TBL] [Abstract][Full Text] [Related]
71. Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma.
Montraveta A; Xargay-Torrent S; López-Guerra M; Rosich L; Pérez-Galán P; Salaverria I; Beà S; Kalko SG; de Frias M; Campàs C; Roué G; Colomer D
Oncotarget; 2014 Feb; 5(3):726-39. PubMed ID: 24519895
[TBL] [Abstract][Full Text] [Related]
72. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
73. Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.
Gupta P; Goldenberg DM; Rossi EA; Cardillo TM; Byrd JC; Muthusamy N; Furman RR; Chang CH
Blood; 2012 Apr; 119(16):3767-78. PubMed ID: 22271448
[TBL] [Abstract][Full Text] [Related]
74. [Refractory CD20-positive peripheral T-cell lymphoma showing loss of CD20 expression after rituximab therapy and gain of CD20 expression after administration of vorinostat and gemcitabine].
Teshima K; Ohyagi H; Kume M; Takahashi S; Saito M; Takahashi N
Rinsho Ketsueki; 2017; 58(11):2227-2231. PubMed ID: 29212973
[TBL] [Abstract][Full Text] [Related]
75. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
Jacobsen E; Freedman A
Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
[TBL] [Abstract][Full Text] [Related]
76. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis.
Hilal T; Wang Z; Almader-Douglas D; Rosenthal A; Reeder CB; Jain T
Am J Hematol; 2018 Oct; 93(10):1220-1226. PubMed ID: 30033656
[TBL] [Abstract][Full Text] [Related]
77. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group.
Determann O; Hoster E; Ott G; Wolfram Bernd H; Loddenkemper C; Leo Hansmann M; Barth TE; Unterhalt M; Hiddemann W; Dreyling M; Klapper W;
Blood; 2008 Feb; 111(4):2385-7. PubMed ID: 18077791
[TBL] [Abstract][Full Text] [Related]
78. Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma.
Alcindor T; Witzig TE
Curr Treat Options Oncol; 2002 Aug; 3(4):275-82. PubMed ID: 12074764
[TBL] [Abstract][Full Text] [Related]
79. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL.
Sohn SK; Baek JH; Kim DH; Jung JT; Kwak DS; Park SH; Suh JS; Lee KB
Am J Hematol; 2000 Sep; 65(1):75-80. PubMed ID: 10936869
[TBL] [Abstract][Full Text] [Related]
80. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens.
Vidal-Crespo A; Matas-Céspedes A; Rodriguez V; Rossi C; Valero JG; Serrat N; Sanjuan-Pla A; Menéndez P; Roué G; López-Guillermo A; Giné E; Campo E; Colomer D; Bezombes C; van Bueren JL; Chiu C; Doshi P; Pérez-Galán P
Haematologica; 2020 Apr; 105(4):1032-1041. PubMed ID: 31296574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
